The first clinical study, which has been published in Heliyon, documents that Vigiis® 101-LAB significantly increases the bacterial counts of Bifidobacterium spp. and Lactobacillus spp. in feces in just one week, and maintains those elevated counts for four weeks.
Thirty-six healthy subjects completed a randomized, double-blind, placebo-controlled 4-week study. The administration group took 50 mg Vigiis® 101-LAB /one capsule/day (= 5 billion NTU 101 CFU/day) for four weeks.
After just one week of administration, the bacterial counts of Bifidobacterium spp. and Lactobacillus spp. in the feces of the treatment group were significantly higher than the placebo group. After four weeks, the treatment group’s bacterial counts of Bifidobacterium spp. and Lactobacillus spp. were 4.01-fold and 4.25-fold higher than the placebo group.
These results indicate that supplementation of Vigiis® 101-LAB significantly increases good bacteria in the gut in just one week and maintains those elevated counts for four weeks. People can benefit from compelling effects of Vigiis® 101-LAB, efficacious and science-supported probiotic.
John Pan, President of SunWay Biotech, commented that “It is important to maintain a healthy microbial balance in the gut microbiome with quality and clinically proven ingredients.”
For more information, please get in touch with us: globalservice@sunway.cc
Reference:
Effects of Vigiis 101-LAB on a healthy population’s gut microflora, peristalsis, immunity, and anti-oxidative capacity: A randomized, double-blind, placebo-controlled clinical study. (link)
Disclaimer: This communication is only intended for business-to-business. Nothing on this page is meant to be perceived as an approved claim by regulatory authorities.
